{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05675722",
            "orgStudyIdInfo": {
                "id": "IRB00091486"
            },
            "organization": {
                "fullName": "Wake Forest University Health Sciences",
                "class": "OTHER"
            },
            "briefTitle": "Implantation Of Vaginal Construct For Patients With Vaginal Aplasia",
            "officialTitle": "Phase 1 Trial Of Implantation Of Vaginal Construct For Patients With Vaginal Aplasia",
            "acronym": "TEV",
            "therapeuticArea": [
                "Other"
            ],
            "study": "implantation-of-vaginal-construct-for-patients-with-vaginal-aplasia"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-29",
            "studyFirstSubmitQcDate": "2022-12-29",
            "studyFirstPostDateStruct": {
                "date": "2023-01-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-28",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-30",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Wake Forest University Health Sciences",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In this Phase 1, single site, clinical trial, Vulvar/vaginal Smooth muscle cells (SMC) and Epithelial Cells (EPC) are isolated from autologous patient's biopsy",
            "detailedDescription": "The cells are expanded in vitro and seeded on scaffold and matured - The final Tissue Engineered Vagina (TEV) is implanted into the native vaginal site"
        },
        "conditionsModule": {
            "conditions": [
                "Congenital Mullerian Duct Anomaly"
            ],
            "keywords": [
                "Vaginal Abnormality"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Ten women, ages 15-45 years, meeting criteria will undergo vaginal/vulva biopsy and biologic vaginal-construct implantation.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "autologous vaginal construct for patients with vaginal aplasia",
                    "type": "EXPERIMENTAL",
                    "description": "Biologic vaginal construct, surgically implanted into native vaginal site",
                    "interventionNames": [
                        "Biological: biologic vaginal-construct implantation"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "biologic vaginal-construct implantation",
                    "description": "biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.",
                    "armGroupLabels": [
                        "autologous vaginal construct for patients with vaginal aplasia"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Serious Adverse Events",
                    "description": "bleeding, pain, visceral injury, vaginal scarring, contraction, or infection",
                    "timeFrame": "Month 36"
                },
                {
                    "measure": "Quality of Life Scores",
                    "description": "The Quality of Life Scores (QOLS) is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112 - the higher score indicates the higher quality of life",
                    "timeFrame": "Baseline"
                },
                {
                    "measure": "Quality of Life Scores",
                    "description": "The Quality of Life Scores (QOLS) is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112 - the higher score indicates the higher quality of life",
                    "timeFrame": "Month 36"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Quality of life Female Sexual Function Index (FSFI) Scores",
                    "description": "The Female Sexual Function Index (FSFI) is a multidimensional measure of female sexual functioning with 19 items that have ordinal, Likert- type response formats and are scored from 0 (or 1) to 5. The scoring algorithm sums items on each domain/sub-scale and then scales the sums so that each subscale has a maximum score of 6 - The FSFI is a survey measuring the sexual functioning of women in six different domains: desire, arousal, lubrication, orgasm, satisfaction and pain - Higher scores indicate better functioning",
                    "timeFrame": "Month 3, Month 6, Month 12, and Month 36"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with congenital Mullerian duct anomaly that includes absence or obliteration of all or part of the vagina, as confirmed on pelvic MRI\n* Females between the ages of 15 and 45 years\n* Patients with stable medical comorbidities\n* Patients that are willing to comply with all study instructions and are willing to return for study follow-up visits\n\nExclusion Criteria:\n\n* Patients with a history of surgery in the target area more recent than the last 6 months\n* Patients with an active vaginal area infection or urinary infection as evidenced by clinical exam or culture result\n* Patients with a history of keloid scarring\n* Patients who are currently taking anti-platelet medications or blood thinners\n* Patients with a history of clotting disorder\n* Patients with autoimmune disease or immune disorder\n* Patients requiring concomitant use of or treatment with immunosuppressive agents\n* Patients with a history of systemic conditions, including but not limited to HIV, thrombocytopenia, uncontrolled diabetes and chronic liver disease (including Hepatitis B or C), that the Investigator believes may jeopardize the safety of the patient to participate in the study\n* Patients with evidence or diagnosis of any primary coagulation disorder (including concomitant anticoagulation therapy at enrollment)\n* Patients who have been treated with any other investigational drug or participated in any investigational study within 30 days prior to enrollment in this study\n* Patients with neurological disorders (e.g., multiple sclerosis, Parkinson's disease)\n* Patients who are current tobacco users\n* Patients with alcohol/drug abuse problems\n* Patients with any systemic disease\n* Patients with any psychiatric disorders\n* Inability to participate in all necessary study activities due to physical or mental limitations.\n* Any circumstance in which the investigator deems participation in the study is not in the subject's best interest\n* The following vital sign cut-off values, laboratory cut-off values and ECG reading will be monitored as the exclusion criteria in the biopsy visit and again before the implantation surgery BP systolic \\>160 or \\<90 millimeters of mercury (mmHg) or diastolic \\>100 or\\<60 millimeters of mercury (mmHg) Pulse \\<60 or \\>105bpm Respiratory Rate \\< 9 and \\>20 Temp \\> 100.4 degrees Fahrenheit Liver enzymes \\>2 times the upper limit of normal (ULN) Abnormal bilirubin unless subject has Gilbert's glomerular filtration rate (eGFR) \\< 60 mL/min/ 1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) HbA1C \\> 8% Hb \\<10 mg/dL Platelet Count \\<100,000 O2 saturation \\<95%\n* If a vital sign or lab value results in exclusion, the subject could be rescreened later",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "genderDescription": "a diagnosis of vaginal agenesis due to a Mullerian duct anomaly",
            "minimumAge": "15 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mary-Clare Day, RN",
                    "role": "CONTACT",
                    "phone": "336.713.1343",
                    "email": "mday@wakehealth.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Catherine Matthews, MD",
                    "affiliation": "Wake Forest University Health Sciences",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Wake Forest University Health Sciences",
                    "status": "RECRUITING",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27157",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mary-Clare Day, RN",
                            "role": "CONTACT",
                            "phone": "336-713-1343",
                            "email": "mday@wakehealth.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M12",
                    "name": "Congenital Abnormalities",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}